We have read with interest the commentary by Siemers et al.  regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.
Watt, A. D., Crespi, G. A. N., Down, R. A., Ascher, D. B., Gunn, A., Perez, K. A., ... Miles, L. A. (2014). Anti-Aβ antibody target engagement: a response to Siemers et al. Acta Neuropathologica, 128(4), 611-4. https://doi.org/10.1007/s00401-014-1333-8